Stockscreener 앱 받기
14.22
3.13%
-0.46
시간 외 거래:
13.18
-1.04
-7.31%
전일 마감가:
$14.68
열려 있는:
$14.3
하루 거래량:
868.35K
Relative Volume:
1.99
시가총액:
$263.25M
수익:
$1.93M
순이익/손실:
$-7.96M
주가수익비율:
-0.00403
EPS:
-3530.8178
순현금흐름:
$-36.78M
1주 성능:
-14.90%
1개월 성능:
-10.96%
6개월 성능:
+20.20%
1년 성능:
+77.97%
1일 변동 폭
$14.09
$15.25
1주일 범위
$14.09
$17.14
52주 변동 폭
$3.39
$20.72
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
14.22 | 271.77M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Guggenheim | Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-05 | 개시 | TD Cowen | Buy |
| 2025-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-03-25 | 개시 | Jefferies | Buy |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-28 | 개시 | Piper Sandler | Overweight |
| 2025-02-21 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-10-24 | 개시 | H.C. Wainwright | Neutral |
| 2024-04-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
모두보기
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AVTX Q4'25 Earnings: revenue estimate is 0 USD - TradingView
Cantor Fitzgerald L. P. Makes New $1.08 Million Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $411,695.80 in Stock - MarketBeat
Avalo Therapeutics chief medical officer sells $411k in stock - Investing.com
Avalo Therapeutics (AVTX) CMO exercises options, sells 25,492 common shares - Stock Titan
Panic Selling: Is Avalo Therapeutics Inc undervalued by DCF analysisOptions Play & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Cantor Fitzgerald L. P. Acquires New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Boxer Capital Management LLC Invests $1.59 Million in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference - MarketBeat
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Can Avalo Therapeutics Inc. stock hit analyst price targets2025 Earnings Surprises & Safe Swing Trade Setups - Naître et grandir
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference - Defense World
FMR LLC holds 2.13M shares of Avalo Therapeutics (NASDAQ: AVTX) — 11.5% - Stock Titan
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX) - The Globe and Mail
Avalo Therapeutics (AVTX) awards 80,000 stock options to Chief Legal Officer - Stock Titan
Avalo Therapeutics (AVTX) CSO awarded 95,000 stock options - Stock Titan
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) CBO awarded 95,000 stock options - Stock Titan
Avalo Therapeutics (AVTX) CFO awarded 105,000 stock options as equity compensation - Stock Titan
Avalo Therapeutics (AVTX) CEO awarded 286,000-share stock option grant - Stock Titan
Millennium Management LLC Acquires Additional Shares in Avalo Th - GuruFocus
RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
AVTX Should I Buy - Intellectia AI
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference - Yahoo Finance
AVTX: AVTX-009 targets central HS inflammation, with pivotal phase II data expected next quarter - TradingView
TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity - Investing.com South Africa
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - MSN
TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity By Investing.com - Investing.com South Africa
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Biotech Avalo, focused on IL‑1β drugs, sets March investor chats - Stock Titan
Patient Square Capital LP Makes New Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
AVTXAvalo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aberdeen Group plc Makes New $925,000 Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Reviewing Avalo Therapeutics (NASDAQ:AVTX) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World
Balyasny Asset Management L.P. Reduces Stake in Avalo Therapeuti - GuruFocus
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Millennium discloses 4.8% Avalo Therapeutics (AVTX) ownership position - Stock Titan
Can Avalo Therapeutics Inc. outperform under higher oil pricesJuly 2025 PreEarnings & Low Risk High Win Rate Picks - mfd.ru
Is Avalo Therapeutics Inc. stock overvalued by current metricsJuly 2025 Final Week & Consistent Profit Trade Alerts - mfd.ru
How Avalo Therapeutics Inc. stock reacts to global recession fearsWeekly Stock Recap & Community Shared Stock Ideas - mfd.ru
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa - MarketBeat
AVTX: Phase 2b LOTUS trial for AVTX-009 in HS nears Q2 data, targeting rapid phase 3 and new indications - TradingView
What analysts say about Avalo Therapeutics Inc. stockJuly 2025 Breakouts & AI Driven Price Forecasts - mfd.ru
SilverArc Capital and Devesh Gandhi report 2.83% Avalo Therapeutics (AVTX) holding - Stock Titan
Dow Update: Will Avalo Therapeutics Inc outperform the market in YEARRate Hike & Long-Term Capital Growth Ideas - baoquankhu1.vn
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):